Session

Liver & biliary (Posters)

SEROPREVALENCE OF HEPATITIS B AND C VIRUSES IN CHILDREN ABOVE THE AGE OF 3 YEARS: AN EGYPTIAN HOSPITAL-BASED CROSS-SECTIONAL SURVEY STUDY
SEROPREVALENCE OF HEPATITIS B AND C VIRUSES IN CHILDREN ABOVE THE AGE OF 3 YEARS: AN EGYPTIAN HOSPITAL-BASED CROSS-SECTIONAL SURVEY STUDY

HUMAN ALPHA-1-DEFENSIN IN PATIENTS WITH ALCOHOLIC HEPATITIS AND LIVER CIRRHOSIS
HUMAN ALPHA-1-DEFENSIN IN PATIENTS WITH ALCOHOLIC HEPATITIS AND LIVER CIRRHOSIS

RELIABILITY OF ALBI AND PALBI SCORES IN PREDICTING THE OCCURRENCE OF COMPLICATIONS IN CIRRHOTIC PATIENTS
RELIABILITY OF ALBI AND PALBI SCORES IN PREDICTING THE OCCURRENCE OF COMPLICATIONS IN CIRRHOTIC PATIENTS

TRANS-ARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: EXPERIENCE OF A TUNISIAN CENTER
TRANS-ARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: EXPERIENCE OF A TUNISIAN CENTER

COMPARISON BETWEEN ACOUSTIC RADIATION FORCE IMPULSE (ARFI) ELASTOGRAPHY AGAINST TRANSIENT ELASTOGRAPHY (FIBROSCAN) IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
COMPARISON BETWEEN ACOUSTIC RADIATION FORCE IMPULSE (ARFI) ELASTOGRAPHY AGAINST TRANSIENT ELASTOGRAPHY (FIBROSCAN) IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

NATURAL HISTORY OF PATIENTS WITH NON-CIRRHOTIC PORTAL HYPERTENSION
NATURAL HISTORY OF PATIENTS WITH NON-CIRRHOTIC PORTAL HYPERTENSION

DEVELOPMENT OF A 90-DAY MORTALITY PREDICTIVE MODEL FOR ALCOHOLIC HEPATITIS
DEVELOPMENT OF A 90-DAY MORTALITY PREDICTIVE MODEL FOR ALCOHOLIC HEPATITIS

ACCURACY OF ULTRASONOGRAPHY FOR DETECTING HEPATIC STEATOSIS IN NAFLD SUSPECTED PATIENTS
ACCURACY OF ULTRASONOGRAPHY FOR DETECTING HEPATIC STEATOSIS IN NAFLD SUSPECTED PATIENTS

PARAMETRIC ARRIVAL TIME (PAT) IN RULING OUT SEVERE LIVER FIBROSIS
PARAMETRIC ARRIVAL TIME (PAT) IN RULING OUT SEVERE LIVER FIBROSIS

HEPATORENAL INDEX AS A NON-INVASIVE MARKER OF NON-ALCOHOLIC FATTY LIVER DISEASE IN CHILDREN
HEPATORENAL INDEX AS A NON-INVASIVE MARKER OF NON-ALCOHOLIC FATTY LIVER DISEASE IN CHILDREN

INSULIN LEVELS ARE ASSOCIATED TO LIVER FUNCTION TEST AND LIVER DISEASE IN COHORTS WITH UP TO 24 YEARS OF FOLLOW-UP
INSULIN LEVELS ARE ASSOCIATED TO LIVER FUNCTION TEST AND LIVER DISEASE IN COHORTS WITH UP TO 24 YEARS OF FOLLOW-UP

FEATURES OF THE SERUM LONG-CHAIN FREE FATTY ACIDS CONTENT IN CHILDREN WITH NON-ALCOHOLIC FATTY LIVER DISEASE
FEATURES OF THE SERUM LONG-CHAIN FREE FATTY ACIDS CONTENT IN CHILDREN WITH NON-ALCOHOLIC FATTY LIVER DISEASE

DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABEL USE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS)
DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABEL USE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS)

NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND SEVERITY OF COVID-19 DISEASE DEPENDING ON THE ITGA2 C807T AND ITGB3 T1565C POLYMORPHISM
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND SEVERITY OF COVID-19 DISEASE DEPENDING ON THE ITGA2 C807T AND ITGB3 T1565C POLYMORPHISM

APOPTOSIS MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE IN CHILDREN
APOPTOSIS MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE IN CHILDREN

ACUTE HAEMODYNAMIC RESPONSE TO INTRAVENOUS PROPRANOLOL PREDICTS DECOMPENSATION AND MORTALITY IN PATIENTS WITH CIRRHOSIS
ACUTE HAEMODYNAMIC RESPONSE TO INTRAVENOUS PROPRANOLOL PREDICTS DECOMPENSATION AND MORTALITY IN PATIENTS WITH CIRRHOSIS

CLINICAL AND PATHOLOGICAL CHARACTERIZATION OF LIVER LYMPHOMAS: A RETROSPECTIVE SINGLE-CENTER STUDY
CLINICAL AND PATHOLOGICAL CHARACTERIZATION OF LIVER LYMPHOMAS: A RETROSPECTIVE SINGLE-CENTER STUDY

LIVER STIFFNESS IS ASSOCIATED WITH DISEASE SEVERITY AND WORSE CLINICAL SCENARIOS IN CORONAVIRUS DISEASE 2019: A PROSPECTIVE TRANSIENT ELASTOGRAPHY STUDY
LIVER STIFFNESS IS ASSOCIATED WITH DISEASE SEVERITY AND WORSE CLINICAL SCENARIOS IN CORONAVIRUS DISEASE 2019: A PROSPECTIVE TRANSIENT ELASTOGRAPHY STUDY

INTRAHEPATIC CHOLESTASIS OF PREGNANCY - WHAT COMES NEXT?
INTRAHEPATIC CHOLESTASIS OF PREGNANCY - WHAT COMES NEXT?

CHRONIC HEPATITIS B GENOTYPE E: CLINICAL CHARACTERISTICS AND RESPONSE TO ANTI-VIRAL AGENTS
CHRONIC HEPATITIS B GENOTYPE E: CLINICAL CHARACTERISTICS AND RESPONSE TO ANTI-VIRAL AGENTS

Item 1 - 20 / 270
1
2 3 4 5 6 7 8 9 10 11 12 13 14